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INFLUENCE OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1) INFECTION ON 
LABORATORY PARAMETERS OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS
Daniela Fernandes CARDOSO(1), Fernando Vieira DE SOUZA(2), Luiz Augusto M. FONSECA(3), Alberto José da Silva DUARTE(4) & Jorge CASSEB(1,4)
SUMMARY
Hepatitis C virus (HCV) and human T-cell lymphotropic virus type 1 (HTLV-1) share routes of transmission and some individuals 
have dual infection. Although some studies point to a worse prognosis of hepatitis C virus in patients co-infected with HTLV-1, the 
interaction between these two infections is poorly understood. This study evaluated the influence of HTLV-1 infection on laboratory 
parameters in chronic HCV patients. Twelve HTLV-1/HCV-coinfected patients were compared to 23 patients infected only with HCV, 
in regard to demographic data, risk factors for viral acquisition, HCV genotype, presence of cirrhosis, T CD4+ and CD8+ cell counts 
and liver function tests. There was no difference in regard to age, gender, alcohol consumption, smoking habits, HCV genotype or 
presence of cirrhosis between the groups. Intravenous drug use was the most common risk factor among individuals co-infected with 
HTLV-1. These patients showed higher TCD8+ counts (p = 0.0159) and significantly lower median values of AST and ALT (p = 0.0437 
and 0.0159, respectively). In conclusion, we have shown that HCV/HTLV-1 co-infected patients differs in laboratorial parameters 
involving both liver and immunological patterns. The meaning of these interactions in the natural history of these infections is a 
matter that deserves further studies.
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INTRODUCTION
Hepatitis C virus (HCV) is the major causative agent of chronic liver 
disease worldwide, with approximately 170 million people infected17,22,25. 
In Brazil, WHO estimates suggest the infection of about three million 
people17. HCV is a single stranded ribonucleic acid (RNA) virus that 
belongs to the Flaviviridae family29 and is transmitted mainly by infected 
blood. Epidemiological studies have revealed that more than 80% 
of acutely HCV-infected patients fail to eradicate the virus, and they 
subsequently develop chronic hepatitis12,14.
Cellular immune responses play an important role in disease 
pathogenesis. The specific T CD8+ response to HCV contributes to 
the viral clearance, but its action is also responsible for the lysis of 
hepatocytes and the consequent development of liver damage in the 
chronic phase3. Several factors can influence the outcome of chronic 
hepatitis C, including age, sex, alcohol consumption15,23 and co-infection 
with other viruses like HIV and HTLV-111,23.
HTLV-1 is a virus belonging to the Retroviridae family that 
preferentially infects CD4+ T cells. Like other retroviruses, HTLV-1 
causes a lifelong infection and is associated with the development of 
adult T-cell leukemia (ATL)36 and HTLV-1-associated myelopathy21. 
Some evidences suggest that HTLV-1 causes a functional impairment 
of the cellular immune response among carriers19,31,35. 
As we know that the development of liver injury is due to stimulation 
of the cytotoxic T lymphocyte response3, we can suppose that the co-
infection between HCV and HTLV-1 may influence the outcome of 
hepatic disease. Although some studies point to a worse prognosis of 
hepatitis C in patients co-infected with HTLV-1, the interaction between 
these two infections is still poorly understood. The aim of this study was 
determine immunological integrity of patients through CD4+ and CD8+ 
lymphocytes counts, and evaluate the influence of HTLV-1 on some 
laboratory parameters of patients with chronic HCV infection. 
MATERIALS AND METHODS
From July to November 2007, 23 consecutive untreated patients 
with chronic hepatitis C from Hepatology Outpatient Clinic followed at 
“Emilio Ribas” Institute of Infectious Diseases (IIER) were included in 
this study. Chronic hepatitis C was defined by detectable anti-hepatitis 
C virus (HCV) and serum viral RNA. HTLV-1/HCV co-infected patients 
were selected from a database made up of patients from the Outpatient 
HTLV Clinic, also followed at IIER. In total, 621 patients were registered 
until September 2007 and 373 were infected with HTLV-1. We found 27 
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patients co-infected with HCV and HTLV-1, from whom only 12 met 
inclusion criteria.
The exclusion criteria included patients with other causes for liver 
disease, infection with the hepatitis B virus (HBV), or HIV. None of 
the patients had received or was receiving antiviral therapy until the 
time of research. Patients were recruited for a blood sample collection 
during their periodic clinical evaluation. This study was approved by the 
Research Ethics Committee of the “Emilio Ribas” Institute of Infectious 
Diseases and all patients gave their informed consent after being briefed 
on the research.
All clinical charts were reviewed to obtain information about socio-
demographic data, risk factors for HCV and HTLV-1 acquisition, HCV 
genotype, existence of cirrhosis and results of the following laboratory 
tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
gamma glutamyl transferase (GGT), alkaline phosphatase (AP), bilirubin, 
albumin, globulin and platelet counts. The analyses of all laboratory tests 
were carried out at the IIER Laboratory.
The diagnosis of cirrhosis was determined by means of a liver biopsy 
indicating fibrosis grade 4, abdominal ultrasound or clinical evidences. 
The histological study was carried out at IIER, and included the analysis 
of the degree of necro-inflammatory activity and the stage of fibrosis, 
which were assessed using a semi-quantitative scoring system according 
to METAVIR classification13.
To determine the counts of CD4+ and CD8+ T-cell subsets, fresh 
whole blood specimens were collected in EDTA tubes and subjected to 
flow cytometry (Coulter® EPICS® XL-MCLÔ Flow Cytometer - Beckman 
Coulter, Fullerton, CA), using human monoclonal antibodies anti-CD3, 
anti-CD4, and anti-CD8, labeled with fluorochrome.
Statistical analysis was performed using Student’s t-test for 
parametric data, and the chi-square test or Fischer’s test for nonparametric 
data. Possible differences in patient characteristics or laboratory values 
among the groups were evaluated with two-way Mann-Whitney’s test 
and Kruskal-Wallis test. Any p value < 0.05 was considered significant.
RESULTS
A total of 35 patients were investigated and their demographic and 
epidemiological data are shown on Table 1. 
There was no statistically significant difference with respect to age, 
gender, alcohol consumption and smoking among HCV/HTLV-1 patients 
compared to those with HCV only. However, with regard to the likely 
risk of viral acquisition, we observed a statistically significant difference 
in the proportion of patients who reported the use of intravenous drugs, 
being higher among co-infected patients (p = 0.01). For both groups, 
a limited number of results from HCV genotypes and liver biopsy 
or ultrasound were available for analysis. There was no statistically 
significant difference in regard to HCV genotype among groups. Although 
the difference was not significant, a relatively lower proportion of co-
infected patients had the diagnosis of cirrhosis.
The results of laboratory tests among HTLV-1/HCV and HCV 
subjects are shown on Table 2.
We observed higher absolute CD8+ T-cell counts among HCV/HTLV-
1 co-infected patients. However, for both groups, the values were within 
the normal ranges. Median values of serum liver enzymes AST, ALT and 
GGT were above the normal range in patients infected only with HCV. 
A statistically significant difference was observed in AST (p = 0.0437) 
and ALT (p = 0.0159) values. No change was observed in bilirubin and 
albumin levels for both groups. On both groups the median globulin 
values were above the normal ranges, and higher values were observed 
among patients infected only with HCV when compared to HCV/HTLV-
1 individuals (p = 0.014). With respect to platelet counts, there was no 
difference between groups.
Table 1







p value aHCV+ (n = 12) HCV +(n = 23)
Age (mean / SD) 44.9 / 14.7 50.4 / 14.1 NS
Gender
     Male 8 (66.7%) 10 (43.5%) NS
     Female 4 (33.3%) 13 (56.5%) NS
Transmission 
route
     IDU 7 (58.4%) 4 (17.4%) 0.01
     Transfusion 3 (25%) 10 (43.5%) NS
     Other /  
     Ignored
2 (16.6%) 9 (39.1%) NS
Alcohol con-
sumption
     Yes 9 (75%) 16 (69.6%) NS
     No 3 (25%) 7 (30.4%) NS
Smoking
     Yes 8 (66.7%) 12 (52.2%) NS
     No 4 (33.3%) 11 (47.8%) NS
Genotype b
     Type 1 5 (41.6%) 14 (60.8%) NS
     Other 1 (8.4%) 0 (0%) NS
     Not done 6 (50%) 9 (39.2%) NS
Presence of 
cirrhosis c
     Yes 1 (8.4%) 5 (21.7%) NS
     No 6 (50%) 13 (56.5%) NS
     Not done 5 (41.6%) 5 (21.8%) NS
SD: Standard deviation; Underlined p values are statistically significant; NS: 
Not significant; a Student’s t test for mean age and Chi-schare test for the others; 
bResults available for only 20 patients; c Results available for only 25 patients.
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DISCUSSION
Co-infection HCV/HTLV-1 is a matter of great interest due to the 
possibility of interactions between these two pathogenic infections. To 
compare the groups, we first evaluated the profile of the patients. No 
difference was observed in age, sex, frequent consumption of alcohol 
and smoking habits between groups. The last two factors are considered 
to possibly affect the progression of liver injury and consequently cause 
greater liver damage18,24, although they did not influence the results shown 
here. The higher number of patients who were intravenous drug users 
suggests that such exposure is an important risk factor for the acquisition 
of HTLV-1 in our cohort of patients. Thus, we can assume that, just as 
happens with patients infected with HTLV-2, infection with HTLV-1 may 
also be linked to drug use and co-infection with HCV4.
The main aim of this study was to relate the presence of infection 
with HTLV-1 with hepatocellular injury, represented by laboratorial data 
of liver function, including the dosage of liver enzymes ALT, AST and 
GGT; quantification of total plasma proteins and their fractions; dosage 
of bilirubin and platelet count. We were able to demonstrate differences 
in concentrations of liver enzymes. In fact, ALT and AST levels were 
statistically lower among HCV/HTLV-1 patients than those infected 
with HCV alone. 
AST is a mitochondrial enzyme present in large quantities in the heart, 
liver, kidney and skeletal muscle. Its serum levels increase when these 
tissues suffer destruction, probably due to release from injured cells. ALT 
is a cytosolic enzyme also present in the liver and increased serum levels 
are more specific for liver injury than AST, because a greater proportion is 
found in the liver compared to the heart and skeletal muscles26. Although 
histological findings on liver biopsy are fundamental to the detection 
of liver disease as well as their intensity, hepatic enzymes changes are 
also used as a biochemical marker for HCV infection and its utility on 
predicting liver damage is described on several studies1,5-7,16,27,37. For 
example, there is evidence that patients with HCV and normal values of 
ALT have milder hepatic injury than those with elevated ALT values5,7,16,27. 
Some authors also correlated serum ALT and AST levels with histologic 
activity score, parameters of disease severity27,37 and extent of fibrosis1.
Although there was no statistically significant difference, higher 
values of GGT were observed among the group infected solely by HCV, 
in spite of the absence of significant differences in alcohol consumption. 
Some authors associated high levels of GGT with more intense necro-
inflammatory activity, suggesting that GGT activity is associated with 
necrosis of hepatocytes. Levels of GGT are also related to the degree 
of hepatic fibrosis28. 
Liver diseases may affect the concentration of circulating plasma 
proteins. The results did not demonstrate any decrease in total plasma 
protein concentration, but the estimation of total plasma protein is not 
accurate. In fact, the serum albumin concentration is more specific and 
widely accepted as a test of liver function, since it reflects the hepatic 
protein synthesis. Likewise no difference between groups and albumin 
concentration was inside normal values, we can assume that in both 
groups the protein hepatic synthesis was preserved. Although on both 
groups globulin level was above normal ranges, this increase was 
lower during HCV/HTLV-1 co-infection. However, globulin is a very 
heterogeneous fraction of plasma proteins, and it is difficult to draw a 
correct conclusion without knowing what fraction would be increased 
in each case. It would be necessary to separate protein fractions through 
electrophoresis, what would enable us answering that question. 
Table 2
Analysis of laboratory results according to HCV infection status
Variable (mean ± SD) HTLV-1 positive HTLV-1 negative p value d
HCV+ (n = 12) HCV+ (n = 23)
CD4 T cells count 1670 ± 364 1159 ± 456 NS
CD8 T cells count 844 ± 217 598 ± 276 0.0159
AST level 36.08 ± 7.84 61.55 ± 39.35 0.0437
ALT level 47.08 ± 31.84 84.3 ± 47.12 0.0159
GGT level 47.27 ± 39.92 126.7 ± 129.3 NS
AP level 91.3 ± 37.9 85.93 ± 37.6 NS
Total bilirubin level 1.06 ± 1.4 0.79 ± 0.41 NS
Indirect bilirubin level 0.80 ± 1.25 0.59 ± 0.39 NS
Direct bilirubin level 0.25 ± 0.21 0.19 ± 0.16 NS
Total protein level 7.4 ± 0.45 7.75 ± 0.55 NS
Albumin level 4.13 ± 0.52 4.09 ± 0.39 NS
Globulin level 3.12 ± 0.53 3.64 ± 0.50 0.014
Platelet count 218200 ± 45350 217400 ± 98930 NS
SD: Standard deviation; Underlined p values are statistically significant; NS: Not significant; d Student’s t test; AST: Asparte aminotransferase; ALT: Alanine amino-
transferase; GGT: Gama glutamyl transferase.
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Taken together, on both groups of patients hepatic function was 
preserved, but co-infected patients have less hepatic injury. Other 
authors have already demonstrated similar results. Unpublished data 
from Miyazaki Cohort Study indicated a possible negative interaction 
between HTLV-1 and HCV with respect to abnormal levels of ALT, with 
the prevalence of elevated ALT levels being lower in co-infected subjects 
than in subjects with HCV alone. Researchers from Japan reported a 
similar effect of co-infection on ALT levels8.
Based on these findings, some authors have postulated that co-
infection with HTLV-1 can reduce the immune-mediated acute damage 
to hepatocytes infected with HCV thereby decreasing the release of 
ALT. At the same time, co-infection increases the persistence of HCV 
infection and, subsequently, the risk of developing liver disease30. As 
several studies have suggested, liver damage is related mainly to immune 
mediated mechanisms, with the stimulation of cytotoxic T cell (CTL) 
response against hepatocytes infected with HCV9,10,20,32. This response 
would lead to hepatocyte lysis and consequent increased release of liver 
transaminases in plasma. 
We also analyzed the number of CD4+ and CD8+ T cells. Although 
within the normal ranges, we have seen higher CD8+ T lymphocyte cells 
among co-infected patients, probably due to response to Tax protein 
of HTLV-133. Despite this increased number of CD8+ T cell, there is a 
reduction of functional immune response, especially of cellular immunity 
in HTLV-1-infected carriers19,31. In persons co-infected with HTLV-1 
and HCV, it is possible to infer that infection of T cells by HTLV-1 may 
interfere with the CTL response to HCV-infected hepatocytes2. 
During the acute phase of infection, a potent T-cell response would 
be an important factor for viral clearance. However, in the chronic phase, 
the activation of CTLs leads to progressive liver damage. We could then 
assume that since the anti-HCV response could be impaired in HTLV-1 
patients, the lysis of hepatocytes infected with HCV would be minor. 
However, this hypothesis should be tested elsewhere.
Thus, in HCV/HTLV-1 co-infected patients, there probably is lower 
immune mediated liver injury, but other factors associated with HTLV-1 
can influence the disease progression, as described in previous works2,30. 
Despite the small sample size of this study, the HCV/HTLV-1 subjects 
showed lower liver enzymatic levels than solely HCV infected subjects. 
This may delay liver biopsy or/and specific anti-HCV treatment. Finally, 
more studies should be done with this population to address histological 
damage, response to treatment and progression to liver disease. 
RESUMO
Influência da infecção pelo vírus linfotrópico humano  
tipo 1 (HTLV-1) em parâmetros laboratoriais de pacientes  
com hepatite C crônica
O vírus da hepatite C (VHC) e vírus linfotrópico humano tipo 1 
(HTLV-1) compartilham formas de transmissão e algumas pessoas 
apresentam coinfecção. Embora alguns estudos apontem para um pior 
prognóstico da infecção pelo VHC em pacientes coinfectados com 
HTLV-1, a interação entre estas infecções é mal compreendida. Este 
estudo avaliou a influência da infecção pelo HTLV-1 em parâmetros 
laboratoriais de pacientes com VHC. 12 coinfectados VHC/HTLV-1 
foram comparados com 23 pacientes monoinfectados com VHC, no que 
diz respeito aos dados demográficos, fatores de risco para aquisição viral, 
genótipo do VHC, presença de cirrose, contagens de linfócitos T CD4+ 
e CD8+ e testes de função hepática. Não houve diferença em relação à 
idade, sexo, consumo de álcool, tabagismo, genótipo do VHC ou presença 
de cirrose entre os grupos. O uso de drogas injetáveis foi o fator de risco 
mais comum entre coinfectados. Esses pacientes apresentaram maiores 
contagens de linfócitos T CD8+ e valores medianos de AST e ALT 
significativamente mais baixos (p = 0,0437 e 0,0159, respectivamente). 
Em conclusão, demonstrou-se que os pacientes com VHC/HTLV-1 
diferem quanto aos parâmetros hepáticos e imunológicos. O significado 
destas diferenças na história natural destas infecções é um assunto que 
merece estudos mais aprofundados.
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